{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:56:13Z","timestamp":1793822173278,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"am","delay-in-days":197,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA50385"],"award-info":[{"award-number":["R01 CA50385"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA176726"],"award-info":[{"award-number":["U01 CA176726"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ajog.2021.12.022","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T20:54:26Z","timestamp":1639601666000},"page":"821.e1-821.e26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3937-4934","authenticated-orcid":false,"given":"Norah A.","family":"Burchardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Heather","family":"Eliassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Shafrir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6907-0056","authenticated-orcid":false,"given":"Bernard","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulla M.","family":"Tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Kaaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-7046","authenticated-orcid":false,"given":"Shelley S.","family":"Tworoger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1426-8505","authenticated-orcid":false,"given":"Ren\u00e9e T.","family":"Fortner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2021.12.022_bib1","first-page":"1","article-title":"Current contraceptive use and variation by selected characteristics among women aged 15-44: United States, 2011-2013","volume":"86","author":"Daniels","year":"2015","journal-title":"In: Natl Health Stat Report"},{"key":"10.1016\/j.ajog.2021.12.022_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0036-1572546","article-title":"The current status of oral contraceptives: progress and recent innovations","volume":"34","author":"Golobof","year":"2016","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.ajog.2021.12.022_bib3","unstructured":"United Nations. Department of Economic and Social Affairs. Population division. Contracept Use Method 2019: Data Booklet;2019. Available\u00a0at: https:\/\/www.un.org\/development\/desa\/pd\/sites\/www.un.org.development.desa.pd\/files\/files\/documents\/2020\/Jan\/un_2019_contraceptiveusebymethod_databooklet.pdf. Accessed February 15, 2021."},{"key":"10.1016\/j.ajog.2021.12.022_bib4","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1055-9965.EPI-13-0298","article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","volume":"22","author":"Gierisch","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2021.12.022_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2021.12.022_bib6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1158\/0008-5472.CAN-20-2476","article-title":"Time-dependent effects of oral contraceptive use on breast, ovarian, and endometrial cancers","volume":"81","author":"Karlsson","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2021.12.022_bib7","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-10-0747","article-title":"Oral contraceptive use and breast cancer: a prospective study of young women","volume":"19","author":"Hunter","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2021.12.022_bib8","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer","volume":"377","author":"M\u00f8rch","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.12.022_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-007-9632-6","article-title":"Epidemiology of basal-like breast cancer","volume":"109","author":"Millikan","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2021.12.022_bib10","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-08-1005","article-title":"Risk factors for triple-negative breast cancer in women under the age of 45 years","volume":"18","author":"Dolle","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2021.12.022_bib11","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/bcr2261","article-title":"Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors","volume":"11","author":"Kwan","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajog.2021.12.022_bib12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/0008-5472.CAN-09-3460","article-title":"Use of four biomarkers to evaluate the risk of breast cancer subtypes in the Women\u2019s Contraceptive and Reproductive Experiences Study","volume":"70","author":"Ma","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2021.12.022_bib13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jnci\/djr030","article-title":"Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer","volume":"103","author":"Phipps","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2021.12.022_bib14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/bjc.2013.807","article-title":"Reproductive risk factors and oestrogen\/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry","volume":"110","author":"Work","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2021.12.022_bib15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1158\/1055-9965.EPI-13-0944","article-title":"Oral contraceptives and breast cancer risk overall and by molecular subtype among young women","volume":"23","author":"Beaber","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2021.12.022_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13058-015-0535-x","article-title":"A\u00a0case-control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium","volume":"17","author":"Bethea","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajog.2021.12.022_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-016-0798-x","article-title":"Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program","volume":"19","author":"Ellingjord-Dale","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajog.2021.12.022_bib18","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1158\/1055-9965.EPI-10-0428","article-title":"Oral contraceptive use and estrogen\/progesterone receptor\u2013negative breast cancer among African American women","volume":"19","author":"Rosenberg","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2021.12.022_bib19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1186\/1471-2407-13-584","article-title":"Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study","volume":"13","author":"Ritte","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajog.2021.12.022_bib20","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/ijc.31266","article-title":"Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: the Norwegian Women and Cancer Study","volume":"142","author":"Busund","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2021.12.022_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrc1608","article-title":"The Nurses\u2019 Health Study: lifestyle and health among women","volume":"5","author":"Colditz","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajog.2021.12.022_bib22","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2105\/AJPH.2016.303338","article-title":"Origin, methods, and evolution of the three Nurses\u2019 Health Studies","volume":"106","author":"Bao","year":"2016","journal-title":"Am J Public Health"},{"key":"10.1016\/j.ajog.2021.12.022_bib23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10654-020-00705-5","article-title":"Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947-1964: The Nurses\u2019 Health Study II, a prospective cohort study","volume":"36","author":"Burchardt","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ajog.2021.12.022_bib24","first-page":"371","article-title":"A\u00a0prospective cohort study of oral contraceptive use and ovarian cancer among women in the United States born from 1947 to 1964","volume":"28","author":"Shafrir","year":"2017","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ajog.2021.12.022_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0010-7824(97)00172-8","article-title":"Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women","volume":"56","author":"Hunter","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2021.12.022_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jnci\/88.6.359","article-title":"Nurses\u2019 health Study: log-incidence mathematical model of breast cancer incidence","volume":"88","author":"Rosner","year":"1996","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2021.12.022_bib27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/aje\/152.10.950","article-title":"Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses\u2019 Health Study","volume":"152","author":"Colditz","year":"2000","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ajog.2021.12.022_bib28","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMcp030751","article-title":"Clinical practice. Combination estrogen-progestin oral contraceptives","volume":"349","author":"Petitti","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.12.022_bib29","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/sim.6793","article-title":"Statistical methods for studying disease subtype heterogeneity","volume":"35","author":"Wang","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.ajog.2021.12.022_bib30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ajog.2021.12.022_bib31","doi-asserted-by":"crossref","first-page":"580.e1","DOI":"10.1016\/j.ajog.2017.02.002","article-title":"Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners\u2019 oral contraception Study","volume":"216","author":"Iversen","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.12.022_bib32","first-page":"1375","article-title":"Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women\u2019s Lifestyle and Health Cohort Study","volume":"11","author":"Kumle","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2021.12.022_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.maturitas.2004.01.001","article-title":"Pharmacological profile of progestins","volume":"47","author":"Sitruk-Ware","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.ajog.2021.12.022_bib34","author":"Davtyan"},{"key":"10.1016\/j.ajog.2021.12.022_bib35","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0002-9378(12)91808-6","article-title":"Sex hormone receptor binding, progestin selectivity, and the new oral contraceptives","volume":"170","author":"Collins","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.12.022_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1783\/147118903101197188","article-title":"Newer progestogens","volume":"29","author":"Rowlands","year":"2003","journal-title":"J\u00a0Fam Plann Reprod Health Care"},{"key":"10.1016\/j.ajog.2021.12.022_bib37","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","article-title":"Classification and pharmacology of progestins","volume":"46","author":"Schindler","year":"2003","journal-title":"Maturitas"},{"key":"10.1016\/j.ajog.2021.12.022_bib38","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ijc.2910520415","article-title":"Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer","volume":"52","author":"Kuenen-Boumeester","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2021.12.022_bib39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/bjc.1998.499","article-title":"Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours","volume":"78","author":"Hall","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2021.12.022_bib40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cncr.11532","article-title":"Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies","volume":"98","author":"Moinfar","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2021.12.022_bib41","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ogc.2015.07.007","article-title":"Does the progestogen used in combined hormonal contraception affect venous thrombosis risk?","volume":"42","author":"Han","year":"2015","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.ajog.2021.12.022_bib52","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10654-020-00705-5","article-title":"Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947-1964: The Nurses\u2019 Health Study II, a prospective cohort study","volume":"36","author":"Burchardt","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ajog.2021.12.022_bib53","author":"Davtyan"},{"key":"10.1016\/j.ajog.2021.12.022_bib54","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/jnci\/djm270","article-title":"Comparison of estrogen receptor results from pathology reports with results from central laboratory testing","volume":"100","author":"Collins","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2021.12.022_bib55","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/bcr2128","article-title":"Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer","volume":"10","author":"Tamimi","year":"2008","journal-title":"Breast Cancer Res"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821026867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821026867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:36:19Z","timestamp":1762079779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937821026867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0002937821026867"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2021.12.022","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}